

## International Conference on Emerging Cell Therapies

October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA

## Cell cycle arrest by jun dimerization protein 2 (JDP2) involves indown-regulation of cyclin A2

Kazunari K. Yokoyama Kaohsiung Medical University, Taiwan

**P**rogression of the cell cycle in mammalian cells is regulated by cyclin-dependentkinases (CDKs) and cdkinhibitors.Cyclin A is a rate-limitingcomponent required for both the initiation of DNA synthesis andentry into mitosis.Jun dimerization protein 2 (JDP2), a member of the AP-1 family, is able to form homodimers, and, also, heterodimers with other members of the AP-1 family, such as c-Jun, JunB, JunD and ATF2, and with a member of the C/EBP family, C/EBPγ. JDP2 most likely participates in the repression of transcription via multiple mechanisms, which include DNA-binding competition and inactivation of formation of heterodimer with other members of the AP-1, recruitment of HDAC 3, inhibition of histone acetylation (H4K16Ac, H4K8Ac, H3Ac) and the direct regulation of chromatin assembly (1). However, the details of the physiological role of JDP2 in cell fate remain unknown. We previously reported that "knock-out" of Jdp2 affects adipocyte differentiation (2) and resistance to replicative senescence (3) and these regulations were proceeded through inhibition of histone acetylation (1, 2) and methylation (3).

We report here a novel role for JDP2 as a regulator of the progression of normal cells through the cell cycle. Fibroblasts derived fromembryos of Jdp2KO mice proliferatedmore rapidly andformed more colonies than wild-type fibroblasts. JDP2 was recruited to the promoter of the gene for cyclin A2 (ccna2) at AP-1 site. Cells lackingJdp2had elevated levels of cyclin A2 mRNA. Moreover, reintroduction of JDP2 resulted in repression of transcription of ccna2 and of cell cycle progression. Thus, transcription of the gene for cyclin A2appears to be a direct target of JDP2 in the suppression of cell proliferation (4)(5).

## Biography

Kazunari K. Yokoyama completed his Ph.D. at University of Tokyo, Department of Science, Division of Biophysics and Biochemistry. He has published more than 230 papers included Nature, Science, Nature Genetics, Molecular Cell, Genes & Development, Nature Structural Biological Chemistry, EMBO J andProcNatlAcadSci USA and serving as peerreviewer of Japanese International Awards of Sciences, Japan Awards and member of American Association for Cancer Research, American Society for Microbiology and International Stem Cell Research.

kazu@kmu.edu.tw